✦ LIBER ✦

Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia

✍ Scribed by Dr. Azra Raza; Harvey D. Preisler; Ya Qin Li; Richard A. Larson; Jack Goldberg; George Browman; John Bennett; Hans Grunwald; Ralph Vogler; Cathi Kukla

Book ID: 102700183
Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 665 KB
Volume: 42
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830420406

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Poor prognosis acute myelogenous leukemi

Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome

✍ Biarou Li; Jie Yang; Ming Tao; Jaya Nayini; Erzsebet Horvath; Harpareet Chopra; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 402 KB

Poor prognosis acute myelogenous leukemi

Poor prognosis acute myelogenous leukemia: 3—biological and molecular biological changes during remission induction therapy

✍ E Devemy; B Li; M Tao; E Horvath; H Chopra; L Fisher; J Nayini; S Creech; P Venu 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 168 KB

The treatment of patients with newly dia

The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure

✍ Harvey D. Preisler; Richard A. Larson; Azra Raza; George Browman; Jack Goldberg; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 590 KB

17q21–qter trisomy is an indicator of po

17q21–qter trisomy is an indicator of poor prognosis in acute myelogenous leukemia

✍ Cristina Morerio; Ivana Russo; Cristina Rosanda; Annamaria Rapella; Anna Leszl; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 795 KB

Financial analysis of patients with newl

Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy

✍ Ellin Berman; Claudia Little; Bonnie Teschendorf; Meaghan Jones; Glenn Heller 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

## Background: Medicare and third-party payers may be reluctant to pay for investigational (protocol) therapy for patients with cancer on the premise that such treatment is more expensive than standard therapy. however, prior studies that have attempted to compare protocol therapy with standard the

162 Potential for use of amifostine in t

162 Potential for use of amifostine in the treatment of poor prognosis acute myelogenous leukemia

✍ H.D. Preisler; X-K. Huang; A. Raza 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 143 KB